IMMX stock Statistics — Immix Biopharma, Inc. filings, insiders & smart money

Price and daily changeSign in

Earnings6 Nov 2026

52-week rangeSign inDay rangeSign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-08-03 · filed common shares: 71.53M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 4.27%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 13.44%
Short ratioDays to cover, as published by FINRA: 5.88
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 65.50%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 56.20%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -34.15%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -31.31%

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-0.88

EPS (fwd)

Cash & equivalentsas of Jun 26: $225.49M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $1.00M
Debt / equityas of Jun 26: 0.44%
Current ratioas of Jun 26: 25.13
Quick ratio: —
Operating cash flowTTM to Jun 26: -$38.49M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$39.08M
TTM revenue / diluted share: —